Carver Kyle 4
4 · Evommune, Inc. · Filed Jul 10, 2026
Research Summary
AI-generated summary of this filing
Evommune (EVMN) CFO Kyle Carver Buys 1,000 Shares
What Happened Kyle Carver, Chief Financial Officer of Evommune, purchased 1,000 shares of Evommune common stock on July 8, 2026 at $13.26 per share, for a total purchase price of $13,260. The transaction is reported on a Form 4 as a purchase (code P), which is a direct buy of company stock.
Key Details
- Transaction date and price: 2026-07-08 — 1,000 shares at $13.26 each (total $13,260).
- Filing date: Form 4 filed 2026-07-10 (appears to be timely).
- Shares owned after transaction: Not disclosed in the filing.
- Notable footnote: The purchase was matchable under Section 16(b) with a prior sale of 1,000 shares on May 28, 2026 at $23.42. Mr. Carver has agreed to pay Evommune $10,160 upon settlement, representing the full short-swing profit.
Context The footnote indicates this purchase triggered a short-swing (Section 16(b)) issue because the insider sold the same number of shares within six months at a higher price; the agreed payment of $10,160 is the disgorgement of that profit (23.42 − 13.26 = $10.16 per share × 1,000). Purchases by executives can be seen as a more informative signal than routine sales, but the disclosed disgorgement means the insider will not retain the short-swing profit from these matched transactions.
Insider Transaction Report
- Purchase
Common Stock
[F1]2026-07-08$13.26/sh+1,000$13,260→ 60,335 total
Footnotes (1)
- [F1]The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction.